(URGN) UroGen Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: IL0011407140

Jelmyto, UGN-102, UGN-103, UGN-104, RTGel

Biotechnology
Market Cap in USD: 1,099m
IPO / Inception: 2017-05-04
12m vs SPY: 57.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of URGN over the last years for every Quarter: "2020-12": -1.38, "2021-03": -1.17, "2021-06": -1.17, "2021-09": -1.35, "2021-12": -1.27, "2022-03": -1.25, "2022-06": -1.18, "2022-09": -1.13, "2022-12": -1.22, "2023-03": -1.3, "2023-06": -1.03, "2023-09": -0.68, "2023-12": -0.72, "2024-03": -0.97, "2024-06": -0.91, "2024-09": -0.55, "2024-12": -0.8, "2025-03": -0.92, "2025-06": -1.05, "2025-09": -0.69, "2025-12": 0,
EPS CAGR: 83.04%
EPS Trend: 69.0%
Last SUE: 3.38
Qual. Beats: 1

Revenue

Revenue of URGN over the last years for every Quarter: 2020-12: 7.966, 2021-03: 7.485, 2021-06: 13.032, 2021-09: 11.351, 2021-12: 16.174, 2022-03: 13.564, 2022-06: 16.604, 2022-09: 16.097, 2022-12: 18.092, 2023-03: 17.192, 2023-06: 21.139, 2023-09: 20.852, 2023-12: 23.53, 2024-03: 18.781, 2024-06: 21.848, 2024-09: 25.204, 2024-12: 24.565, 2025-03: 20.254, 2025-06: 24.215, 2025-09: 27.482, 2025-12: null,
Rev. CAGR: 15.18%
Rev. Trend: 87.5%
Last SUE: -2.99
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 79.4%
Value at Risk 5%th 98.6%
Relative Tail Risk -24.51%
Reward TTM
Sharpe Ratio 1.09
Alpha 62.97
CAGR/Max DD 0.38
Character TTM
Hurst Exponent 0.640
Beta 1.061
Beta Downside 1.118
Drawdowns 3y
Max DD 82.64%
Mean DD 32.39%
Median DD 33.50%

Description: URGN UroGen Pharma December 01, 2025

UroGen Pharma Ltd. (NASDAQ: URGN) is a U.S.-based biotech focused on developing and commercializing polymer-based drug delivery systems for urothelial and specialty cancers, leveraging its proprietary reverse-thermal gel (RTGel) platform.

The current pipeline centers on three late-stage candidates: UGN-102 (approved Jelmyto® for low-grade upper-tract urothelial carcinoma), UGN-103 (Phase 3 intravesical therapy for non-muscle-invasive bladder cancer, NMIBC) and UGN-104 (Phase 3 intrapelvic solution targeting low-grade NMIBC). Early-stage programs include UGN-301-based regimens (Phase 1) aimed at high-grade NMIBC.

UroGen has strategic collaborations that expand its commercial reach: a license with Agenus Inc. to co-develop intravesical products for urinary-tract cancers, and a development-supply agreement with medac GmbH for UGN-103 and UGN-104.

Key quantitative signals (as of Q2 2024) include a cash runway of roughly $120 million, a 27 % YoY increase in R&D spend reflecting intensified Phase 3 activity, and a market estimate of > $1.5 billion for NMIBC therapies in the United States-an area where polymer-based delivery could command premium pricing. The broader biotech sector continues to benefit from a 9 % annual growth in venture capital funding, supporting late-stage oncology innovators.

For a deeper, data-driven look at URGN’s valuation dynamics, you may find the analytics on ValueRay worth a quick scan.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-164.6m TTM) > 0 and > 6% of Revenue (6% = 5.79m TTM)
FCFTA -0.75 (>2.0%) and ΔFCFTA -42.70pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 130.9% (prev 293.5%; Δ -162.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.74 (>3.0%) and CFO -137.7m > Net Income -164.6m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (48.1m) change vs 12m ago 11.50% (target <= -2.0% for YES)
Gross Margin 87.95% (prev 90.27%; Δ -2.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 39.64% (prev 29.60%; Δ 10.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -5.36 (EBITDA TTM -130.7m / Interest Expense TTM 24.7m) >= 6 (WARN >= 3)

Altman Z'' -18.88

(A) 0.68 = (Total Current Assets 168.5m - Total Current Liabilities 42.2m) / Total Assets 185.0m
(B) -5.04 = Retained Earnings (Balance) -933.4m / Total Assets 185.0m
warn (B) unusual magnitude: -5.04 — check mapping/units
(C) -0.54 = EBIT TTM -132.5m / Avg Total Assets 243.5m
(D) -3.11 = Book Value of Equity -933.2m / Total Liabilities 300.5m
Total Rating: -18.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 48.51

1. Piotroski 1.0pt
2. FCF Yield -12.54%
3. FCF Margin data missing
4. Debt/Equity -1.13
5. Debt/Ebitda -0.31
7. RoE 249.4%
8. Rev. Trend 87.46%
9. EPS Trend 68.97%

What is the price of URGN shares?

As of January 15, 2026, the stock is trading at USD 18.74 with a total of 1,491,449 shares traded.
Over the past week, the price has changed by -19.01%, over one month by -17.99%, over three months by +12.55% and over the past year by +88.72%.

Is URGN a buy, sell or hold?

UroGen Pharma has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy URGN.
  • Strong Buy: 5
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the URGN price?

Issuer Target Up/Down from current
Wallstreet Target Price 35.3 88.1%
Analysts Target Price 35.3 88.1%
ValueRay Target Price 22.2 18.4%

URGN Fundamental Data Overview January 10, 2026

P/S = 11.3826
P/B = 19.2691
Revenue TTM = 96.5m USD
EBIT TTM = -132.5m USD
EBITDA TTM = -130.7m USD
Long Term Debt = 122.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.59m USD (from shortTermDebt, last quarter)
Debt = 129.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 39.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.10b USD (1.10b + Debt 129.9m - CCE 127.0m)
Interest Coverage Ratio = -5.36 (Ebit TTM -132.5m / Interest Expense TTM 24.7m)
EV/FCF = -7.97x (Enterprise Value 1.10b / FCF TTM -138.1m)
FCF Yield = -12.54% (FCF TTM -138.1m / Enterprise Value 1.10b)
FCF Margin = -143.1% (FCF TTM -138.1m / Revenue TTM 96.5m)
Net Margin = -170.6% (Net Income TTM -164.6m / Revenue TTM 96.5m)
Gross Margin = 87.95% ((Revenue TTM 96.5m - Cost of Revenue TTM 11.6m) / Revenue TTM)
Gross Margin QoQ = 88.07% (prev 85.34%)
Tobins Q-Ratio = 5.95 (Enterprise Value 1.10b / Total Assets 185.0m)
Interest Expense / Debt = 6.15% (Interest Expense 7.99m / Debt 129.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -104.7m (EBIT -132.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.99 (Total Current Assets 168.5m / Total Current Liabilities 42.2m)
Debt / Equity = -1.13 (negative equity) (Debt 129.9m / totalStockholderEquity, last quarter -115.4m)
Debt / EBITDA = -0.31 (negative EBITDA) (Net Debt 39.9m / EBITDA -130.7m)
Debt / FCF = -0.29 (negative FCF - burning cash) (Net Debt 39.9m / FCF TTM -138.1m)
Total Stockholder Equity = -66.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.62% (Net Income -164.6m / Total Assets 185.0m)
RoE = 249.4% (negative equity) (Net Income TTM -164.6m / Total Stockholder Equity -66.0m)
RoCE = -236.2% (out of range, set to none) (EBIT -132.5m / Capital Employed (Equity -66.0m + L.T.Debt 122.1m))
RoIC = -186.6% (out of range, set to none) (NOPAT -104.7m / Invested Capital 56.1m)
WACC = 9.30% (E(1.10b)/V(1.23b) * Re(9.82%) + D(129.9m)/V(1.23b) * Rd(6.15%) * (1-Tc(0.21)))
Discount Rate = 9.82% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.29%
Fair Price DCF = unknown (Cash Flow -138.1m)
EPS Correlation: 68.97 | EPS CAGR: 83.04% | SUE: 3.38 | # QB: 1
Revenue Correlation: 87.46 | Revenue CAGR: 15.18% | SUE: -2.99 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.51 | Chg30d=+0.069 | Revisions Net=-1 | Analysts=6
EPS next Year (2026-12-31): EPS=-1.10 | Chg30d=-0.506 | Revisions Net=+1 | Growth EPS=+65.1% | Growth Revenue=+123.2%

Additional Sources for URGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle